← back to search

Jing Liu

Peking University · CN
Area of research
Molecular Biology · Spectroscopy
Research interest
Research interests include Cancer-related gene regulation, Epigenetics and DNA Methylation, Analytical Chemistry and Chromatography, and RNA modifications and cancer.
h-index
47
citations
10,601
works
264
NIH funding
primary concept
Chemistry
email

Recent publications

Development of a brain-penetrant G9a methylase inhibitor to target Alzheimer's disease-associated proteopathology.
2025cited by 5position: contributordoi
Discovery of a Potent, Selective, and Cell-Active SPIN1 Inhibitor
Journal of Medicinal Chemistry 2024cited by 3position: middledoi
Clinical biomarkers for thyroid immune-related adverse events in patients with stage III and IV gastrointestinal tumors
Frontiers in Immunology 2024cited by 3position: middledoi
Regional quantification of cardiac metabolism with hyperpolarized [1 - <sup>13</sup> C]-pyruvate MRI evaluated in an oral glucose challenge
medRxiv 2023cited by 1position: middledoi
Novel brain-penetrant inhibitor of G9a methylase blocks Alzheimer’s disease proteopathology for precision medication
2023cited by 1position: contributordoi
PRMT inhibition induces a viral mimicry response in triple-negative breast cancer.
2022cited by 93position: contributordoi
Photoredox-Enabled Chromium-Catalyzed Alkene Diacylations
ACS Catalysis 2022cited by 66position: firstdoi
Inactive and active state structures template selective tools for the human 5-HT5A receptor
Nature Structural & Molecular Biology 2022cited by 28position: middledoi
Inactive and active state structures template selective tools for the human 5-HT&lt;sub&gt;5A&lt;/sub&gt; receptor.
2022cited by 21position: contributordoi
Pharmacologic modulation of RNA splicing enhances anti-tumor immunity
Cell 2021cited by 274position: middledoi
Structure, function and pharmacology of human itch GPCRs
Nature 2021cited by 221position: middledoi
Structure, function and pharmacology of human itch GPCRs
Nature 2021cited by 213position: contributordoi
A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models.
2021cited by 117position: contributordoi
Probing the SAM Binding Site of SARS-CoV-2 Nsp14 In Vitro Using SAM Competitive Inhibitors Guides Developing Selective Bisubstrate Inhibitors
SLAS DISCOVERY 2021cited by 89position: middledoi
Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders
Nature Cancer 2021cited by 72position: middledoi
Methylation of dual-specificity phosphatase 4 controls cell differentiation
Cell Reports 2021cited by 34position: middledoi
Altered RNA splicing initiates the viral mimicry response from inverted SINEs following type I PRMT inhibition in Triple-Negative Breast Cancer
2021cited by 1position: contributordoi
Deschloroclozapine, a potent and selective chemogenetic actuator enables rapid neuronal and behavioral modulations in mice and monkeys
Nature Neuroscience 2020cited by 423position: middledoi
Deschloroclozapine, a potent and selective chemogenetic actuator enables rapid neuronal and behavioral modulations in mice and monkeys.
2020cited by 355position: contributordoi
Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders.
2020cited by 138position: contributordoi
Discovery of First-in-Class Protein Arginine Methyltransferase 5 (PRMT5) Degraders.
2020cited by 76position: contributordoi
Discovery of First-In-Class Potent and Selective Tropomyosin Receptor Kinase Degraders.
2020cited by 40position: contributordoi
Discovery of a First-in-Class Protein Arginine Methyltransferase 6 (PRMT6) Covalent Inhibitor.
2020cited by 33position: contributordoi
A chemical biology toolbox to study protein methyltransferases and epigenetic signaling.
2019cited by 101position: contributordoi
Discovery of a First-in-Class Mitogen-Activated Protein Kinase Kinase 1/2 Degrader.
2019cited by 56position: contributordoi
Discovery of a Potent and Selective Fragment-like Inhibitor of Methyllysine Reader Protein Spindlin 1 (SPIN1)
Journal of Medicinal Chemistry 2019cited by 34position: middledoi
Designing Functionally Selective Noncatechol Dopamine D<sub>1</sub> Receptor Agonists with Potent In Vivo Antiparkinsonian Activity.
2019cited by 28position: contributordoi
Discovery of a Potent and Selective Fragment-like Inhibitor of Methyllysine Reader Protein Spindlin 1 (SPIN1).
2019cited by 28position: contributordoi
Design, Synthesis, and Characterization of Ogerin-Based Positive Allosteric Modulators for G Protein-Coupled Receptor 68 (GPR68).
2019cited by 27position: contributordoi
Defining Structure-Functional Selectivity Relationships (SFSR) for a Class of Non-Catechol Dopamine D<sub>1</sub> Receptor Agonists.
2019cited by 20position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

Jian Jin · Icahn School of Medicine at Mount Sinai14 papers (2019–2025) · 10 papers (2019–2025)Jian Jin · Zhengzhou Central Hospital8 papers (2015–2024)Bryan L. Roth · University of North Carolina at Chapel Hill7 papers (2017–2022)Masoud Vedadi · Ontario Institute for Cancer Research5 papers (2015–2024)Fengling Li · Weifang Medical University5 papers (2015–2024) · 5 papers (2019–2022)Cheryl H. Arrowsmith · University of British Columbia5 papers (2019–2022)Yan Xiong · Jiujiang University4 papers (2019–2024)Brian K. Shoichet · Quantitative BioSciences4 papers (2017–2022)C.H. Arrowsmith · University Health Network4 papers (2015–2024)Dalia Baršytė-Lovejoy · University of Toronto3 papers (2015–2019)Matthieu Schapira · University Health Network3 papers (2015–2021)Peter J. Brown · Columbia University3 papers (2015–2021)Kwang-Su Park · Keimyung University3 papers (2021–2025)Dalia Barsyte-Lovejoy · Nature Research Centre3 papers (2019–2022) · 3 papers (2019–2024) · 2 papers (2019–2024)Vsevolod Katritch · QB32 papers (2022–2022)Stephen V. Frye · University of North Carolina at Chapel Hill2 papers (2013–2016)